ID: ALA3143517

Max Phase: Preclinical

Molecular Formula: C31H43N5O5

Molecular Weight: 565.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)c1cc(C[C@H]2NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)CCCCNC(=O)CCNC2=O)ccc1O

Standard InChI:  InChI=1S/C31H43N5O5/c1-31(2,3)22-17-21(12-13-26(22)37)19-25-29(40)34-16-14-27(38)33-15-8-7-11-24(30(41)36-25)35-28(39)23(32)18-20-9-5-4-6-10-20/h4-6,9-10,12-13,17,23-25,37H,7-8,11,14-16,18-19,32H2,1-3H3,(H,33,38)(H,34,40)(H,35,39)(H,36,41)/t23-,24-,25+/m0/s1

Standard InChI Key:  RRXAKVUZGASTMY-CCDWMCETSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 565.72

Molecular Weight (Monoisotopic): 565.3264

AlogP: 1.58

#Rotatable Bonds: 6

Polar Surface Area: 162.65

Molecular Species: NEUTRAL

HBA: 6

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.10

CX Basic pKa: 7.71

CX LogP: 1.94

CX LogD: 1.46

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.31

Np Likeness Score: 0.55

References

1. Haramura M, Okamachi A, Tsuzuki K, Yogo K, Ikuta M, Kozono T, Takanashi H, Murayama E..  (2002)  Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin.,  45  (3): [PMID:11806718] [10.1021/jm010332u]

Source

Source(1):

• Scientific Literature